ArticleChem2019
Nanoscale Metal-Organic Framework Mediates Radical Therapy to Enhance Cancer Immunotherapy.
Article in Chem, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 205 citations in OpenAlex.
- ROS-mediated Therapeutics Combined with Metal-based Porphyrin Nanoparticles and their Applications in Tumor Treatment.Current medicinal chemistry · 2025Review
- Hyaluronic acid-functionalized supramolecular nanophotosensitizers for targeted photoimmunotherapy of triple-negative breast cancer.Journal of nanobiotechnology · 2024Article
- Photodynamic Therapy-Induced Anti-Tumor Immunity: Influence Factors and Synergistic Enhancement Strategies.Pharmaceutics · 2023Review
- The Application of Biomedicine in Chemodynamic Therapy: From Material Design to Improved Strategies.Bioengineering (Basel, Switzerland) · 2023Review
- Microfluidic synthesis of fibronectin-coated polydopamine nanocomplexes for self-supplementing tumor microenvironment regulation and MR imaging-guided chemo-chemodynamic-immune therapy.Materials today. Bio · 2023Article
- Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Review
- Photoactivatable nanoagonists chemically programmed for pharmacokinetic tuning and in situ cancer vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Hybrid Nanomaterials for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Research Progress of Nanomedicine-Based Mild Photothermal Therapy in Tumor.International journal of nanomedicine · 2023Review
- Protein Binding Nanoparticles as an Integrated Platform for Cancer Diagnosis and Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Application of MOF-based nanotherapeutics in light-mediated cancer diagnosis and therapy.Journal of nanobiotechnology · 2022Review
- Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications.Pharmaceutics · 2022Review
- Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy.Journal of nanobiotechnology · 2022Review
- Strategies for enhancing cancer chemodynamic therapy performance.Exploration (Beijing, China) · 2022Review
- Iron oxide nanoparticles as a drug carrier reduce host immunosuppression for enhanced chemotherapy.Nanoscale · 2022Article
- Cascade-responsive nanobomb with domino effect for anti-tumor synergistic therapies.National science review · 2022Article
- Fenton metal nanomedicines for imaging-guided combinatorial chemodynamic therapy against cancer.Asian journal of pharmaceutical sciences · 2022Review
- Red Blood Cell-Mimic Nanocatalyst Triggering Radical Storm to Augment Cancer Immunotherapy.Nano-micro letters · 2022Article
- Tumor-specific activatable biopolymer nanoparticles stabilized by hydroxyethyl starch prodrug for self-amplified cooperative cancer therapy.Theranostics · 2022Article
Corrections and comments
- Retraction · 2023-03-09Duplication of/in Image · Original Data and/or Images not Provided and/or not Available · · see also: https://pubpeer.com/publications/44A2C2BA17E06385071BF5863340F1
- Retracted
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Checkpoint blockade immunotherapy (CBI) elicits durable therapeutic responses by blocking T cell inhibitory pathways of tumors with pre-infiltrated T cells and/or high mutational burden to activate antitumor immunity but is ineffective against poorly immunogenic tumors. Immunogenic radiotherapy, photodynamic therapy (PDT), and chemotherapy have thus been examined as immunomodulatory adjuvants to augment CBI. Dysregulated hormone production has long been linked to tumorigenesis and poor prognosis of various cancers. Herein, we report the use of a Cu-porphyrin nanoscale metal-organic framework (nMOF) to mediate synergistic hormone-triggered chemodynamic therapy (CDT) and light-triggered PDT. The combination of CDT/PDT-based radical therapy with a programmed cell-death ligand 1 blockade effectively extends the local therapeutic effects of CDT/PDT to distant tumors via abscopal effects on mouse tumor models with high levels of estradiol. Our work thus establishes the feasibility of combining nMOF-mediated radical therapy with CBI to elicit systemic antitumor immunity in hormonally dysregulated tumor phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.